Students walk through Harvard Yard during commencement ceremonies at Harvard University, Thursday, May 29, 2025, in Cambridge, Mass. (AP Photo/Charles Krupa)
for a transplant, and many experts acknowledge there never will be enough human donors to meet the need.Animals offer the tantalizing promise of a ready-made supply. After decades of failed attempts, companies including Revivicor,
and Makana Therapeutics are engineering pigs to be more humanlike.So far in the U.S. there have been four “compassionate use” transplants, last-ditch experiments into dying patients — two hearts and two kidneys. Revivicor provided both hearts and one of the kidneys. While the four patients died within a few months, they offered valuable lessons for researchers ready to try again in people who aren’t quite as sick.Now the FDA is evaluating promising results from experiments in donated human bodies and awaiting results of additional studies of pig organs in baboons before deciding next steps.
They’re semi-custom organs — “we’re growing these pigs to the size of the recipient,” Ayares noted — that won’t show the wear-and-tear of aging or chronic disease like most organs donated by people.Transplant surgeons who’ve retrieved organs on Revivicor’s farm “go, ‘Oh my god that’s the most beautiful kidney I’ve ever seen,’” Ayares added. “Same thing when they get the heart, a pink healthy happy heart from a young animal.”
PIgs stand in pens at the Revivicor research farm near Blacksburg, Va., on May 29, 2024, where organs are retrieved for animal-to-human transplant experiments. (AP Photo/Shelby Lum)
PIgs stand in pens at the Revivicor research farm near Blacksburg, Va., on May 29, 2024, where organs are retrieved for animal-to-human transplant experiments. (AP Photo/Shelby Lum)“Is the pharmacist going to determine if you’re in a high-risk group?” asked Dr. Paul Offit, a vaccine expert at Children’s Hospital of Philadelphia. “The only thing that can come of this will make vaccines less insurable and less available.”
The nation’s leading pediatrics group said FDA’s approach will limit options for parents and their children.“If the vaccine were no longer available or covered by insurance, it will take the choice away from families who wish to protect their children from COVID-19, especially among families already facing barriers to care,” said Dr. Sean O’Leary of the American Academy of Pediatrics.
Provisional data from the Centers for Disease Control and Prevention shows more than 47,000 Americans died from COVID-related causes last year. The virus was the underlying cause for two-thirds of those and it was a contributing factor for the rest. Among them were 231 children whose deaths were deemed COVID-related, 134 of them where the virus was the direct cause -- numbers similar to yearly pediatric deaths from the flu.The new FDA approach is the culmination of a